No single appetite stimulant stands out as definitively “best” for all cancer patients, and major oncology guidelines reflect that reality. Both the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) acknowledge that only two drug classes, progestins and corticosteroids, have consistently shown benefits for appetite and body weight, yet neither organization endorses a specific pharmacological standard of care for cancer cachexia.1PubMed. Management of Cancer Cachexia: ASCO Guideline 2PubMed Central. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines The choice depends on the patient’s specific symptoms, cancer type, treatment plan, and tolerance for side effects. Several drugs have genuine evidence behind them, and a few newer options are generating real excitement.
Why Cancer Destroys Appetite in the First Place
Cancer-related appetite loss is not just about feeling sick from chemotherapy. Nearly half of cancer patients develop cachexia, a metabolic syndrome in which the body breaks down fat and muscle at an accelerated rate regardless of how much a person eats.3PubMed Central. Neural Mechanisms of Cancer Cachexia Tumors release inflammatory molecules that act on the brain’s appetite-regulating centers, essentially resetting the hunger thermostat downward. Chemotherapy and radiation can pile on by causing nausea, altering taste and smell, and slowing the stomach’s ability to empty food. Because the problem has multiple drivers, no pill addresses every layer at once, which is why different drugs work better for different patients.
Megestrol Acetate
Megestrol acetate, a synthetic progestin originally developed for hormone-sensitive cancers, is the most widely studied appetite stimulant in oncology. A Cochrane systematic review concluded that it improves appetite compared with placebo and is associated with modest weight gain in cancer patients.4PubMed Central. Megestrol acetate for treatment of anorexia-cachexia syndrome An early controlled trial found that about 16% of cancer patients on megestrol gained at least 15 pounds, compared with just 2% on placebo, and patients consistently reported better appetite and food intake.5Journal of the National Cancer Institute. Controlled Trial of Megestrol Acetate for the Treatment of Cancer Anorexia and Cachexia
The picture is less rosy when you look more closely at the numbers. A 2022 meta-analysis pooling results across multiple dosages found that the average weight change from megestrol was under one kilogram and did not reach statistical significance.6PubMed Central. A Systematic Review and Meta-Analysis of the Clinical Use of Megestrol Acetate for Cancer-Related Anorexia/Cachexia So megestrol reliably makes people feel hungrier, but whether that hunger translates into meaningful weight or muscle recovery is inconsistent across studies. Weight gained on megestrol also tends to be fat and water rather than lean muscle, which limits the functional benefit.
Safety is the other concern. Megestrol raises the risk of blood clots. One study of patients prescribed megestrol for appetite found roughly a threefold increase in venous thromboembolism after adjusting for other risk factors.7Journal of Hospital Medicine. Incidence of Venous Thromboembolism (Vte) in Patients Prescribed Megestrol for Appetite Stimulation Cancer patients are already at elevated clotting risk, so this is not a trivial addition. Some researchers have argued that the blood-clot risk is more attributable to the cancer itself and concurrent chemotherapy than to megestrol directly.8PubMed. Hemostatic effects of high-dose megestrol acetate therapy in patients with advanced gynecological cancer Either way, clinicians tend to weigh this risk carefully, especially in patients with a history of clots or who are on other pro-coagulant treatments. Megestrol can also suppress the body’s natural cortisol production, meaning it cannot be stopped abruptly without risking adrenal insufficiency.
Corticosteroids
Dexamethasone and prednisolone are the corticosteroids most commonly used to boost appetite in advanced cancer. They work fast, often improving how a patient feels about food within a day or two. For that reason, they are frequently prescribed in palliative settings where short-term comfort is the primary goal. ASCO guidelines specify that corticosteroid use for appetite should be limited to weeks, not months, because side effects accumulate quickly: muscle wasting, high blood sugar, immune suppression, and mood changes all become problematic with longer courses.1PubMed. Management of Cancer Cachexia: ASCO Guideline
The irony of corticosteroids is that prolonged use worsens the very muscle loss they are meant to counteract. A randomized trial comparing megestrol, dexamethasone, and placebo found that about two-thirds of dexamethasone patients improved appetite at one week, versus about 58% on placebo, but the difference between either active drug and placebo did not reach statistical significance.9PubMed Central. A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer This trial was a reminder that the placebo effect is real in appetite research: when patients are enrolled in a trial and receive extra attention and monitoring, many feel hungrier regardless of what pill they take.
Olanzapine
Olanzapine, better known as an antipsychotic, is emerging as one of the more promising appetite stimulants for cancer patients. Oncologists already use low-dose olanzapine to prevent chemotherapy-induced nausea and vomiting, so its appetite-boosting side effect (well known from psychiatric practice, where weight gain is an unwanted consequence) is being repurposed as a feature rather than a bug.
A randomized, placebo-controlled trial in patients with advanced gastric, hepatopancreaticobiliary, and lung cancers found that 60% of patients on olanzapine gained more than 5% of their body weight, compared with 9% on placebo. Appetite scores improved in about 43% of the olanzapine group versus 13% on placebo, and quality of life was better across several measures.10PubMed. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer A systematic review and meta-analysis corroborated these findings, reporting that olanzapine significantly improved appetite scores compared with both placebo and active comparators.11PubMed. Effects of olanzapine in the improvement of body weight and appetite in patients with cancer or receiving chemotherapy: a systematic review and meta-analysis The doses used are low, typically 2.5 to 5 mg taken once daily at bedtime, and side effects in the cancer trials were minimal.12PubMed Central. A Review of Olanzapine in the Treatment of Cancer Anorexia-Cachexia Syndrome
Olanzapine has a practical advantage: it simultaneously manages nausea, insomnia, and anxiety, all of which are common in cancer patients undergoing treatment and all of which independently suppress appetite. The main limitation is that the evidence base, while striking, still rests on a relatively small number of trials. Guideline committees have not yet elevated it to the same recommendation level as megestrol or corticosteroids, but the data are strong enough that many oncologists are already prescribing it off-label for appetite.
Anamorelin and the Ghrelin Pathway
Ghrelin is the hormone your stomach releases to tell your brain you are hungry. Anamorelin is an oral drug that mimics ghrelin’s action, and it has performed well in large trials. In the ROMANA 1 and ROMANA 2 phase 3 trials involving patients with advanced non-small-cell lung cancer and cachexia, anamorelin increased lean body mass by roughly 0.6 to 1 kilogram over 12 weeks while placebo patients lost lean mass.13PubMed. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials A Japanese trial showed similar lean-mass gains and also found significant improvement in anorexia symptoms at every measured time point.14PubMed Central. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia
The catch is that anamorelin increased lean mass without improving handgrip strength in any of these trials.13PubMed. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials This disconnect between body composition and physical function is one reason regulatory agencies in the United States and Europe have not approved it, while Japan has. For patients and families, that distinction matters: gaining a kilogram of lean tissue sounds encouraging, but if you still cannot open a jar or walk to the mailbox, the benefit is harder to feel in daily life. That said, anamorelin was generally well tolerated, and it remains one of the few drugs that has shown consistent lean-mass gains in large trials.
Mirtazapine
Mirtazapine is an antidepressant whose weight-gain side effect has made it a natural candidate for appetite stimulation in cancer. It works on serotonin and histamine receptors in ways that both increase hunger and help with sleep. An open-label pilot study in advanced cancer patients found that weight increased significantly by four and seven weeks, alongside improvements in depression scores and overall quality of life.15PubMed. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms A more rigorous randomized trial in non-small-cell lung cancer patients showed that mirtazapine significantly reduced anxiety scores, though the appetite-specific results were less clear-cut in the data reported.16JAMA Oncology. Mirtazapine as Appetite Stimulant in Patients With Non–Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial
Where mirtazapine shines is in patients who are also dealing with depression, anxiety, or insomnia alongside their appetite loss. In those cases, a single drug addressing several problems at once can simplify treatment and reduce the pill burden. Sedation is the most common side effect, but because the drug is taken at bedtime, that sedation often doubles as a sleep aid. Mirtazapine has not yet accumulated the volume of cachexia-specific trial data that megestrol or olanzapine have, so it tends to be used when those comorbid symptoms make it a particularly good fit.
Cannabinoids
Many patients and families assume that cannabis or pharmaceutical cannabinoids like dronabinol and nabilone should be powerful appetite stimulants, given their well-known effect on “the munchies” in healthy people. The clinical data, unfortunately, are underwhelming. A systematic review examining five trials of medicinal cannabis products for appetite in cancer patients found that only one trial demonstrated significant efficacy, and that was specifically for improving taste perception and the proportion of calories eaten as protein rather than for overall food intake or weight gain.17PubMed. Efficacy of medicinal cannabis for appetite-related symptoms in people with cancer: A systematic review A small pilot study using dosage-controlled cannabis capsules did find that patients self-reported less appetite loss after treatment, but the study was too small to draw firm conclusions.18PubMed Central. The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study
The gap between public perception and trial results here is striking. Cancer cachexia involves inflammatory signaling that is fundamentally different from the hunger regulation cannabinoids tap into in healthy brains. That does not mean cannabis products are useless for cancer patients, since many find them helpful for nausea, pain, and mood, but as appetite stimulants specifically, the evidence does not support them as a first-line choice.
Metoclopramide for Gastroparesis-Driven Appetite Loss
Not all cancer-related appetite loss stems from the brain’s hunger circuits. In patients with upper gastrointestinal tumors in particular, the stomach itself may be the problem. About 70% of patients with upper GI tumors who complained of early fullness and satiety in one study had objectively delayed stomach emptying.19PubMed. Tumor-associated gastroparesis: correction with metoclopramide Metoclopramide, a prokinetic drug that speeds up gastric emptying, produced measurable improvement in all ten patients studied, and those who responded gained weight and were able to tolerate outpatient cancer treatment.20Journal of Palliative Care. Metoclopramide in Anorexia Caused by Cancer-Associated Dyspepsia Syndrome (CADS)
Metoclopramide is not an appetite stimulant in the traditional sense. It does not make you hungrier. Instead, it clears the physical bottleneck that prevents a patient from eating a full meal. If you eat three bites and feel uncomfortably full because your stomach is not emptying, a drug that fixes the emptying problem can dramatically change your food intake without touching a single hunger hormone. This is why a careful assessment of the cause of appetite loss matters before picking a drug.
Non-Drug Strategies That Actually Help
Pharmacology gets most of the attention, but exercise and nutritional counseling have evidence behind them too, and they address a weakness that no pill has yet solved: physical function. A pooled analysis of trials combining supervised exercise with nutritional counseling found that handgrip strength improved significantly over three months in the intervention group compared with controls.21PubMed Central. Effect of combined therapies including nutrition and physical exercise in advanced cancer patients: A pooled analysis This is noteworthy because, as discussed in the anamorelin section, drugs that increase lean body mass have not translated into strength gains. Exercise appears to fill that gap.
Resistance training, even at low intensity, can help preserve muscle mass and improve how patients feel day to day. Nutritional counseling by a registered dietitian can address practical barriers: meal timing, calorie-dense foods, managing taste changes, and supplementing with high-protein drinks between meals. A review of multidisciplinary non-pharmacological interventions concluded that combining exercise and nutrition with standard care could meaningfully improve quality of life and prognosis.22PubMed Central. Nutritional and Exercise Interventions in Cancer-Related Cachexia: An Extensive Narrative Review These approaches are not a replacement for medication when appetite loss is severe, but they are an important complement.
Fish Oil and EPA Supplements
Eicosapentaenoic acid, the omega-3 fatty acid found in fish oil, was once thought to be a promising anti-cachexia supplement because of its anti-inflammatory properties. The theory was reasonable: if inflammatory signaling drives cachexia, an anti-inflammatory nutrient might interrupt the cycle. A Cochrane review, however, found no evidence that EPA improves symptoms of cancer cachexia, even when added to protein-calorie supplementation alongside an appetite stimulant like megestrol.23PubMed Central. Eicosapentaenoic acid for the treatment of cancer cachexia Fish oil is not harmful and may have other health benefits, but recommending it specifically for cancer appetite loss is not supported by the current evidence.
How Clinicians Actually Choose
In practice, the drug chosen depends less on head-to-head superiority data (there is precious little of that) and more on the patient’s symptom profile. A patient with severe nausea from chemotherapy who is also losing weight is a natural candidate for olanzapine, which tackles both problems. A patient in the final weeks of life who simply wants to enjoy a meal with family may benefit most from a short course of dexamethasone. A patient with months of treatment ahead who needs sustained appetite support might be started on megestrol, with careful monitoring for blood clots. A patient whose depression and insomnia are compounding their appetite loss might do best on mirtazapine. And a patient with a pancreatic or gastric tumor who feels full after a few bites may need metoclopramide before any appetite stimulant can work.
The ASCO guideline explicitly states that clinicians may reasonably choose to prescribe no pharmacological treatment for cachexia at all, given the modest evidence.1PubMed. Management of Cancer Cachexia: ASCO Guideline That is not nihilism. It reflects the honest state of the science: appetite stimulants tend to make people feel hungrier and sometimes gain weight, but no drug has convincingly shown it can reverse cachexia, restore muscle function, or extend survival. The goal is symptom relief and quality of life, and setting that expectation up front helps patients and families judge whether a drug trial is worthwhile.
Targeting GDF15 and Future Directions
The most scientifically interesting development in cancer appetite research involves a molecule called GDF15. Tumors secrete GDF15, and it activates a specific receptor in the hindbrain that powerfully suppresses appetite. Unlike the broad inflammatory signals that drive cachexia generally, GDF15 represents a specific, targetable pathway. Researchers have discovered that selpercatinib, a drug already approved for certain RET-driven cancers, can block the downstream signaling of GDF15 and mitigate cachexia independently of any anti-tumor effect in preclinical models.24PubMed Central. Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model
This line of research is still early, based on animal models rather than human trials, but it represents a fundamentally different approach. Instead of broadly stimulating appetite with hormones or neurotransmitter manipulation, it blocks the specific tumor-derived signal telling the brain not to eat. Several pharmaceutical companies are developing anti-GDF15 antibodies and GFRAL receptor blockers, and clinical trials in cancer patients are expected to report results over the next few years. If the approach works in humans the way it works in mice, it could be the first treatment that actually addresses a root cause of cancer anorexia rather than just overriding it.